← Back to Screener
Verastem, Inc. (VSTM)
Price$6.34
Favorite Metrics
Price vs S&P 500 (26W)-33.18%
Price vs S&P 500 (4W)8.03%
Market Capitalization$556.00M
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)14.26x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)128.24%
Cash Flow / Share (Quarterly)$-1.89
Price vs S&P 500 (YTD)-20.65%
Gross Margin (TTM)85.12%
Net Profit Margin (TTM)-509.05%
EPS (TTM)$-2.13
10-Day Avg Trading Volume1.95M
EPS Excl Extra (TTM)$-2.13
Revenue Growth (5Y)-18.97%
EPS (Annual)$-3.02
ROI (Annual)-145.64%
Gross Margin (Annual)82.86%
Net Profit Margin (5Y Avg)-1674.50%
Cash / Share (Quarterly)$2.64
ROA (Last FY)-85.00%
Revenue Growth TTM (YoY)209.14%
EBITD / Share (TTM)$-2.14
ROE (5Y Avg)-154.64%
Operating Margin (TTM)-407.43%
Cash Flow / Share (Annual)$-1.89
P/B Ratio9.72x
P/B Ratio (Quarterly)10.17x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)14.16x
Net Interest Coverage (TTM)-314.86x
ROA (TTM)-76.20%
EPS Incl Extra (Annual)$-3.02
Current Ratio (Annual)3.09x
Quick Ratio (Quarterly)2.96x
3-Month Avg Trading Volume1.91M
52-Week Price Return32.43%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.52
P/S Ratio (Annual)17.99x
Asset Turnover (Annual)0.13x
52-Week High$11.24
Operating Margin (5Y Avg)-1512.87%
EPS Excl Extra (Annual)$-3.02
CapEx CAGR (5Y)217.14%
Tangible BV CAGR (5Y)-3.85%
26-Week Price Return-29.19%
Quick Ratio (Annual)2.96x
13-Week Price Return-10.97%
Total Debt / Equity (Annual)1.51x
Current Ratio (Quarterly)3.09x
Enterprise Value$437.64
Revenue / Share Growth (5Y)-42.22%
Asset Turnover (TTM)0.15x
Book Value / Share Growth (5Y)-7.04%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-677.59%
Cash / Share (Annual)$2.64
3-Month Return Std Dev68.11%
Gross Margin (5Y Avg)87.71%
Net Income / Employee (TTM)$-2
ROE (Last FY)-366.23%
Net Interest Coverage (Annual)-147.60x
EPS Basic Excl Extra (Annual)$-3.02
Receivables Turnover (TTM)0.35x
Total Debt / Equity (Quarterly)1.51x
EPS Incl Extra (TTM)$-2.13
Receivables Turnover (Annual)0.00x
ROI (TTM)-44.66%
P/S Ratio (TTM)17.99x
Pretax Margin (5Y Avg)-1674.08%
Revenue / Share (Annual)$0.45
Tangible BV / Share (Annual)$0.52
Price vs S&P 500 (52W)2.60%
Year-to-Date Return-18.01%
5-Day Price Return13.24%
EPS Normalized (Annual)$-3.02
ROA (5Y Avg)-83.02%
Net Profit Margin (Annual)-677.59%
Month-to-Date Return19.43%
Cash Flow / Share (TTM)$-3.92
EBITD / Share (Annual)$-3.06
Operating Margin (Annual)-556.24%
LT Debt / Equity (Annual)1.42x
ROI (5Y Avg)-90.60%
LT Debt / Equity (Quarterly)1.42x
EPS Basic Excl Extra (TTM)$-2.13
P/TBV (Quarterly)14.26x
P/B Ratio (Annual)10.17x
Inventory Turnover (TTM)21.26x
Pretax Margin (TTM)-509.05%
Book Value / Share (Annual)$0.74
Price vs S&P 500 (13W)-11.66%
Beta0.51x
Revenue / Share (TTM)$0.37
ROE (TTM)-126.22%
52-Week Low$4.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VSTMVerastem, Inc. | 17.99x | 209.14% | 85.12% | — | $6.34 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Verastem Inc is a late-stage development biopharmaceutical company developing novel anticancer agents targeting critical signaling pathways in cancer. The company's pipeline is focused on RAF/MEK and FAK inhibition to suppress cancer cell survival and tumor growth.